Clinical trials
Liposarcoma clinical trials
Below are recruiting liposarcoma clinical trials, each written for real people, not researchers. We’re tracking 31 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06843967RecruitingPhase 1/Phase 2
Mirdametinib and palbociclib for liposarcoma
This trial tests two targeted drugs – mirdametinib and palbociclib – taken as pills for people with a specific aggressive type of liposarcoma (dedifferentiated liposarcoma) that has spread or can't be removed. The goal is to see if this combination can shrink or slow the tumor.
Basking Ridge, New JerseyAges 18 years+ - NCT06239272RecruitingPhase 1/Phase 2
Personalized treatment for NRSTS in children and young adults
This trial tests a personalized treatment plan for children and young adults with a type of soft tissue sarcoma (NRSTS). It uses a combination of surgery, targeted radiation, and two drugs (pazopanib and selinexor) to fight cancer while reducing side effects. The study is looking for people who have not been treated before for this sarcoma.
Atlanta, GeorgiaAges Up to 30 years - NCT02275286RecruitingPhase 1/Phase 2
Trabectedin plus radiation for select soft tissue sarcomas
This trial studies whether adding a chemotherapy medicine called trabectedin to targeted radiation can help control certain soft tissue sarcomas. It focuses on specific cancer types and locations, aiming to shrink tumors while keeping radiation safe for nearby healthy organs.
BordeauxAges 18 years+ - NCT07261657RecruitingEarly Phase 1
N-803 for progressive sarcoma after T-cell therapy
This trial tests a drug called N-803 for people with synovial sarcoma or myxoid/round cell liposarcoma that has gotten worse after T-cell therapy. N-803 may help the immune system fight the cancer, and the study will see if it can slow or stop the cancer from growing.
Chicago, IllinoisAges 18–80 - NCT06025747RecruitingPhase 1
Abemaciclib plus radiation for liposarcoma before surgery
This trial tests a combination of the targeted drug abemaciclib and radiation therapy before surgery for people with a specific type of liposarcoma. The goal is to see if this combination can shrink the tumor and help make surgery more effective.
Seattle, WashingtonAges 18 years+ - NCT06422806RecruitingPhase 3
Immunotherapy plus chemo for aggressive sarcoma
This trial compares a combination of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) versus chemotherapy alone for people with aggressive, poorly differentiated sarcomas that have spread or cannot be removed. The goal is to see if adding immunotherapy helps shrink tumors or slow their growth better than chemotherapy alone.
Phoenix, ArizonaAges 18 years+ - NCT07432932Recruiting
Personalized treatment before surgery for high-risk sarcoma
This trial tests a precision medicine approach by giving targeted therapy before surgery for high-risk soft tissue sarcoma. The goal is to see if matching treatment to your tumor's type can improve outcomes.
LondonAges 18 years+ - NCT04224064Recruiting
Blood test to help diagnose and predict liposarcoma
This study looks for a new blood test marker that may help doctors diagnose liposarcoma and estimate how it may behave over time. You may be asked for a blood sample and consent, and the study may follow you to see how well the test works.
MontpellierAges 18 years+ - NCT07377747Recruiting
Study of treatment for recurrent retroperitoneal liposarcoma
This study looks at how well standard treatments work for people whose liposarcoma has come back in the same area. It helps doctors understand best ways to manage this rare cancer.
Atlanta, GeorgiaAges 18 years+ - NCT04785196RecruitingPhase 1/Phase 2
Testing an MDM2 drug plus an immune therapy for advanced tumors
This trial tests APG-115 together with a PD-1 immune therapy in people with advanced liposarcoma or other advanced solid tumors. It may help by blocking tumor growth through a mix of direct tumor targeting and immune system activation.
Guangzhou, GuangdongAges 18 years+ - NCT07173972RecruitingPhase 2
Proton radiation for inoperable soft tissue sarcoma
This trial studies a high-dose, shortened course of proton beam radiation for people with soft tissue sarcoma that cannot be removed by surgery. It aims to improve tumor control while reducing side effects.
BergenAges 18 years+ - NCT06957431RecruitingPhase 1
Zanzalintinib and eribulin for advanced leiomyosarcoma and liposarcoma
This trial tests a combination of two drugs, zanzalintinib and eribulin, for people with advanced leiomyosarcoma or liposarcoma that has progressed after prior treatment. The goal is to see if this combination can help shrink or slow the growth of these sarcomas.
St Louis, MissouriAges 18 years+ - NCT06498648RecruitingPhase 1/Phase 2
Abemaciclib with gemcitabine for soft tissue sarcoma
This trial tests whether adding the targeted drug abemaciclib to standard chemotherapy (gemcitabine) works better against certain soft tissue sarcomas. It is for people whose tumors have a normal Rb gene, which may help the drug work.
Houston, TexasAges 18 years+ - NCT06389799RecruitingPhase 2
Pemigatinib and Retifanlimab for Advanced Liposarcoma
This trial tests two experimental drugs (pemigatinib and retifanlimab) for advanced dedifferentiated liposarcoma that has not responded to other treatments. It aims to see if this combination can shrink tumors or slow cancer growth.
OsloAges 18–100 - NCT05711615RecruitingPhase 1
Low-dose doxorubicin plus peposertib for advanced sarcoma
This Phase 1 trial tests a low dose of a common chemotherapy (liposomal doxorubicin) together with an anti-cancer drug called peposertib. It’s for people with advanced sarcoma that can’t be cured, aiming to find a safe dosing plan and see how well the treatment might work.
Los Angeles, CaliforniaAges 18 years+ - NCT04699292Recruiting
Registry study for local treatment in soft tissue sarcoma
This registry collects coded information about adults with a specific soft tissue sarcoma (MLS) to better understand how local treatments help. If you qualify, you don’t necessarily receive a new drug in this study—your data is used to improve future care.
AmsterdamAges 18 years+ - NCT06436846Recruiting
Genomic risk in retroperitoneal sarcoma
This study is looking at genetic risk factors in people with retroperitoneal liposarcoma who are having surgery to remove the tumor. The goal is to understand how genes affect the disease and possibly guide future treatments.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07741877RecruitingPhase 2
Immune cells for advanced soft tissue sarcoma
This trial tests a treatment made from your own immune cells, called tumor-infiltrating lymphocytes, to see if they can shrink or slow down advanced soft tissue sarcoma. It might be an option if you have tried other treatments and your cancer is still growing.
Tampa, FloridaAges 16–70 - NCT07169344RecruitingPhase 2
Short course radiation before sarcoma surgery
This trial tests a shorter, 3-week course of radiation therapy (using protons or standard X-rays) given before surgery for localized soft tissue sarcoma. It aims to see if this approach is safe and effective for treating the tumor while reducing side effects.
BergenAges 18 years+ - NCT07148050RecruitingPhase 1
CAR T-cell therapy for children with solid tumors
This trial tests a new kind of immunotherapy for children and teens with solid tumors that have not responded to standard treatments. The therapy uses specially engineered T cells (CAR T cells) that target a protein called GPC3 found on many tumor cells, and it includes extra signals (IL-15 and IL-21) to help the T cells work better.
Seattle, WashingtonAges 1–26 - NCT06975293RecruitingPhase 1/Phase 2
STC-15 with toripalimab for advanced cancers and sarcomas
This trial tests a new drug called STC-15, either alone or with another drug (toripalimab), for people with certain advanced cancers or sarcomas that have progressed after prior treatment. The goal is to see if this combination or single drug can help shrink tumors or slow the disease.
San Francisco, CaliforniaAges 18 years+ - NCT06849986RecruitingPhase 2
Immunotherapy & AI for first-line soft tissue sarcoma
This trial tests a combination of immunotherapy (a treatment that helps your immune system attack cancer) and artificial intelligence (AI) technology as the first treatment for certain types of advanced soft tissue sarcoma. It aims to see if this approach can shrink tumors or stop them from growing better than current options.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06789172RecruitingPhase 1
New drug OKN4395 with or without pembrolizumab for solid tumors
This trial tests a new oral drug called OKN4395, which targets a COX2-related immune pathway, alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors. It may be an option if you have certain types of cancer that have stopped responding to other treatments.
Beverly Hills, CaliforniaAges 18 years+ - NCT06277154RecruitingPhase 2
MASCT-I plus chemo for first-line advanced soft tissue sarcoma
This trial tests a new immune cell therapy (MASCT-I) combined with standard chemotherapy (doxorubicin and ifosfamide) for people with advanced soft tissue sarcoma who have not had prior chemotherapy or targeted therapy. The goal is to see if the combination works better than chemo alone.
GuangzhouAges 18–70
Hear when a new Liposarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Liposarcoma trials by city
Studies with a site in or near these metro areas.
Liposarcoma trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for liposarcoma?
- Yes. Clin2 currently lists 31 recruiting liposarcoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a liposarcoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a liposarcoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.